NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ARWR

Arrowhead Pharmaceuticals Inc

Jul 01 • 04:00PM ET

16.09

Dollar change +0.29
Percentage change 1.84	%

Healthcare • Biotechnology • USA • NASD

Peers: ALNY IONS SRPT NBIX DTIL VRTX RGNX CRSP EDIT NTLA

| Held by: IJR VTI IWM VB VXF XBI VBK IWO SPSM IJS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.38	Insider Own	16.58%	Shs Outstand	138.06M	Perf Week	0.81%
Market Cap	2.22B	Forward P/E	-	EPS next Y	-3.40	Insider Trans	-2.64%	Shs Float	115.20M	Perf Month	0.12%
Enterprise Value	1.87B	PEG	-	EPS next Q	-0.95	Inst Own	74.55%	Short Float	11.01%	Perf Quarter	26.30%
Income	-143.97M	P/S	4.08	EPS this Y	103.90%	Inst Trans	5.25%	Short Ratio	6.94	Perf Half Y	-17.61%
Sales	545.21M	P/B	3.25	EPS next Y	-1840.62%	ROA	-11.39%	Short Interest	12.68M	Perf YTD	-14.41%
Book/sh	4.95	P/C	2.02	EPS next 5Y	9.33%	ROE	-24.67%	52W High	30.41 -47.09%	Perf Year	-37.37%
Cash/sh	7.95	P/FCF	483.05	EPS past 3/5Y	-54.48% -	ROIC	-10.65%	52W Low	9.57 68.13%	Perf 3Y	-53.31%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-70.50% -53.80%	Gross Margin	96.13%	Volatility	5.57% 4.58%	Perf 5Y	-59.53%
Dividend TTM	-	EV/Sales	3.42	EPS Y/Y TTM	68.03%	Oper. Margin	-21.74%	ATR (14)	0.82	Perf 10Y	116.26%
Dividend Ex-Date	-	Quick Ratio	5.15	Sales Y/Y TTM	1436.97%	Profit Margin	-26.41%	RSI (14)	54.09	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	5.15	EPS Q/Q	371.04%	SMA20	-0.11%	Beta	0.95	Target Price	41.77
Payout	-	Debt/Eq	1.08	Sales Q/Q	-	SMA50	6.52%	Rel Volume	0.69	Prev Close	15.80
Employees	609	LT Debt/Eq	0.98	Earnings	May 12 AMC	SMA200	-10.06%	Avg Volume	1.83M	Price	16.09
IPO	Dec 16, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	722.17% 332.80%	Trades		Volume	1,282,991	Change	1.84%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-24	Initiated	Goldman	Neutral	$31
Dec-04-23	Initiated	BofA Securities	Buy	$29
Sep-19-23	Initiated	Citigroup	Neutral	$33
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform	$40
Apr-26-23	Initiated	SMBC Nikko	Outperform	$80
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform	$21 → $35
Mar-21-23	Initiated	Bernstein	Mkt Perform	$27
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$41
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform	$71 → $60
Jan-19-22	Resumed	Goldman	Buy	$90 → $85
Aug-06-21	Reiterated	Chardan Capital Markets	Buy	$97 → $94
Jun-04-21	Resumed	Robert W. Baird	Neutral	$85
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$90 → $95
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral	$75
Dec-16-20	Initiated	UBS	Buy	$95
Nov-19-20	Initiated	Citigroup	Buy	$90
May-13-20	Initiated	RBC Capital Mkts	Outperform	$62
May-08-20	Upgrade	Oppenheimer	Perform → Outperform	$58
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$55 → $60

Show Previous Ratings

Jul-01-25 05:32AM	Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 \| Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth (GlobeNewswire)
Jun-23-25 07:30AM	Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran (Business Wire)
Jun-05-25 05:10AM	Jim Cramer on Arrowhead Pharmaceuticals (ARWR): "It Doesn't Make Any Money" (Insider Monkey)
Jun-03-25 08:28PM	Lightning Round: Buy Dover right now, says Jim Cramer (CNBC TV)
05:37AM	Arrowhead commences dosing in Phase I/IIa obesity treatment trial (Clinical Trials Arena)
07:30AM	Loading…
Jun-02-25 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity (Business Wire)
May-29-25 07:30AM	Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences (Business Wire) +8.10%
May-13-25 03:07AM	Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ... (GuruFocus.com) +9.38%
May-12-25 04:10PM	Arrowhead Research: Fiscal Q2 Earnings Snapshot (Associated Press Finance) +7.21%
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results (Business Wire)
May-07-25 02:14PM	Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating (Seeking Alpha)
12:14PM	Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade (Seeking Alpha)
08:31AM	SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut (Zacks)
07:30AM	Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences (Business Wire)
May-05-25 07:49AM	Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential (Insider Monkey)
04:01PM	Loading…
Apr-30-25 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results (Business Wire)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Apr-19-25 05:30AM	ClearBridge Small Cap Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-15-25 04:00PM	Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer (Business Wire) -11.81%
Apr-04-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -11.44%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-24-25 08:25AM	How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion (Zacks)
Mar-21-25 05:56PM	Arrowhead Pharmaceuticals Is Finally Arriving (SeekingAlpha)
Mar-10-25 02:02PM	Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases (Benzinga) -10.37%
07:30AM	Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy (Business Wire)
Mar-06-25 08:45AM	Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases (Business Wire)
Feb-28-25 09:00AM	Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) (Business Wire)
Feb-25-25 07:30AM	Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity (Business Wire)
Feb-20-25 12:15PM	Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now (Insider Monkey)
Feb-11-25 10:10AM	Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -5.17%
02:06AM	Loading…
02:06AM	Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ... (GuruFocus.com)
Feb-10-25 04:08PM	Arrowhead Research: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results (Business Wire)
08:30AM	Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics (Business Wire)
Jan-22-25 05:54PM	Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600 (PR Newswire) +9.23%
04:00PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results (Business Wire)
Jan-17-25 04:30PM	Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome (Business Wire)
Dec-24-24 08:20AM	Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial (Clinical Trials Arena)
Dec-23-24 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity (Business Wire)
Dec-19-24 04:59PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Dec-11-24 07:30AM	Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases (Business Wire)
Dec-04-24 07:40AM	Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment (Clinical Trials Arena) -11.35%
Dec-03-24 07:30AM	Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity (Business Wire)
Dec-02-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences (Business Wire)
Nov-30-24 06:00AM	Arrowhead price target lowered to $24 from $27 at Bernstein (TipRanks)
Nov-29-24 01:00AM	Arrowhead Pharmaceuticals Faces Distribution Risks with Vanscoy Reliance (TipRanks)
Nov-28-24 08:15AM	Sarepta price target lowered to $202 from $205 at Needham (TipRanks)
Nov-27-24 12:40PM	Q4 2024 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +24.23%
11:07AM	Arrowhead Stock Rockets 16% After Major Licensing Deal (GuruFocus.com)
07:21AM	Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments (TipRanks)
07:20AM	Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board (TipRanks)
04:33AM	Arrowhead and Sarepta link for rare genetic disease treatments (Pharmaceutical Technology)
02:04AM	Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ... (GuruFocus.com)
Nov-26-24 05:18PM	Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal (Investor's Business Daily) +12.03%
04:05PM	Arrowhead Pharma, Sarepta TX ink new gene therapy deal (Yahoo Finance Video)
04:00PM	Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results (Business Wire)
09:06AM	Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta (Investor's Business Daily)
07:00AM	Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs (Business Wire)
07:00AM	Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs (Business Wire)
Nov-22-24 07:41AM	Arrowhead Pharmaceuticals Inc. (ARWR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-19-24 03:38AM	Arrowhead Pharmaceuticals submits plozasiran NDA to treat FCS (Pharmaceutical Business Review)
Nov-18-24 07:31AM	Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome (Business Wire)
07:30AM	Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran (Business Wire)
Nov-05-24 07:30AM	Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results (Business Wire)
Nov-04-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences (Business Wire)
Nov-01-24 07:30AM	Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, Well Get There Soon, to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome (Business Wire)
Oct-16-24 01:01PM	State Street Corp's Strategic Acquisition in Arrowhead Pharmaceuticals (GuruFocus.com) +6.14%
Oct-14-24 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Oct-09-24 05:53PM	Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com)
Sep-24-24 06:53AM	Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand (Clinical Trials Arena)
Sep-23-24 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity (Business Wire)
Sep-11-24 06:12AM	FDA grants breakthrough therapy status to Arrowheads plozasiran (Pharmaceutical Technology)
Sep-10-24 07:30AM	Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran (Business Wire)
Sep-03-24 10:36AM	Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug (Investopedia)
06:33AM	Arrowhead to file NDA after pivotal rare disease trial meets all endpoints (Clinical Trials Arena)
Sep-02-24 06:36AM	Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome (Business Wire)
Aug-21-24 07:30AM	Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome (Business Wire) +6.95%
Aug-16-24 06:00AM	Zealand, Arrowhead advance obesity drugs; Bluebird narrows guidance (BioPharma Dive)
Aug-15-24 10:52AM	Arrowhead announces push into obesity space with two gene therapies (Pharmaceutical Technology)
Aug-14-24 01:30PM	Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies (Business Wire)
Aug-08-24 04:37PM	Arrowhead Research: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -9.44%
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results (Business Wire)
04:00PM	Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street (Business Wire)
Jul-29-24 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-24-24 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results (Business Wire)
Jun-28-24 06:50AM	Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 (InvestorPlace)
Jun-25-24 01:55PM	Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial (Business Wire)
Jun-24-24 07:30AM	Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE (Business Wire) +6.82%
Jun-03-24 03:55PM	Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday? (Benzinga) +7.28%
07:30AM	Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome (Business Wire)
May-31-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences (Business Wire)
May-29-24 05:30AM	Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia (Business Wire)
May-28-24 06:04AM	Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia (Business Wire)
May-20-24 11:04AM	Arrowhead Pharmaceuticals Lung Disease Treatment Study Shows Lower Serum sRAGE in Asthma Patients (MT Newswires)
06:00AM	Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma (Business Wire)
May-14-24 07:08AM	Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 (InvestorPlace)
May-10-24 01:03PM	Arrowhead Pharmaceuticals Reports Substantial Fiscal Q2 Loss, Diverging from Analyst Expectations (GuruFocus.com) -10.68%
12:26PM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript (Insider Monkey)
11:32AM	UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating (MT Newswires)
May-09-24 11:54PM	ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q2 2024 (InvestorPlace)

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anzalone Christopher Richard	Chief Executive Officer	Apr 11 '25	Sale	11.49	50,800	583,692	3,921,255	Apr 11 06:20 PM
Anzalone Christopher Richard	Chief Executive Officer	Apr 10 '25	Sale	10.87	50,000	543,500	3,972,055	Apr 11 06:20 PM
Anzalone Christopher Richard	Chief Executive Officer	Apr 09 '25	Sale	10.07	40,322	406,145	4,022,055	Apr 11 06:20 PM
Anzalone Christopher Richard	Officer	Apr 11 '25	Proposed Sale	11.49	50,800	583,751		Apr 11 04:29 PM
Anzalone Christopher Richard	Officer	Apr 10 '25	Proposed Sale	10.86	50,000	543,215		Apr 10 04:35 PM
Anzalone Christopher Richard	Officer	Apr 09 '25	Proposed Sale	10.07	40,322	406,057		Apr 09 04:44 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 13 '25	Sale	15.07	51,425	774,975	4,062,377	Mar 17 05:45 PM
Anzalone Christopher Richard	Officer	Mar 13 '25	Proposed Sale	15.07	51,425	774,785		Mar 13 04:46 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 03 '25	Option Exercise	7.75	166,667	1,291,669	3,940,469	Mar 05 06:32 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 04 '25	Option Exercise	7.75	133,333	1,033,331	4,073,802	Mar 05 06:32 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 03 '25	Sale	18.03	166,667	3,005,006	3,907,135	Mar 05 06:32 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 04 '25	Sale	17.02	133,333	2,269,328	3,773,802	Mar 05 06:32 PM
Anzalone Christopher Richard	Officer	Mar 04 '25	Proposed Sale	17.02	133,333	2,268,742		Mar 04 05:48 PM
Anzalone Christopher Richard	Officer	Mar 03 '25	Proposed Sale	18.03	166,667	3,004,203		Mar 03 05:09 PM
OLUKOTUN ADEOYE Y	Director	Jan 23 '25	Sale	21.00	959	20,139	35,781	Jan 27 07:22 PM
OLUKOTUN ADEOYE Y	Director	Jan 23 '25	Proposed Sale	20.97	959	20,108		Jan 23 04:43 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jan 06 '25	Sale	19.82	32,729	648,824	272,122	Jan 07 09:28 PM
O'Brien Patrick	COO and General Counsel	Jan 06 '25	Sale	19.82	29,184	578,539	535,201	Jan 07 09:28 PM
O'Brien Patrick	COO and General Counsel	Jan 07 '25	Sale	19.69	8,000	157,520	527,201	Jan 07 09:28 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 06 '25	Sale	19.83	27,167	538,595	473,433	Jan 07 09:27 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 07 '25	Sale	19.69	18,000	354,500	455,433	Jan 07 09:27 PM
Myszkowski Kenneth Allen	Officer	Jan 07 '25	Proposed Sale	19.69	10,000	196,877		Jan 07 05:01 PM
Myszkowski Kenneth Allen	Officer	Jan 07 '25	Proposed Sale	19.69	8,000	157,529		Jan 07 04:49 PM
O'Brien Patrick	Officer	Jan 07 '25	Proposed Sale	19.69	8,000	157,507		Jan 07 04:31 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 02 '25	Sale	19.05	11,520	219,456	3,764,252	Jan 06 06:07 PM
Myszkowski Kenneth Allen	Officer	Jan 06 '25	Proposed Sale	19.82	5,817	115,318		Jan 06 05:48 PM
Myszkowski Kenneth Allen	Officer	Jan 06 '25	Proposed Sale	19.82	9,255	183,476		Jan 06 05:40 PM
Myszkowski Kenneth Allen	Officer	Jan 06 '25	Proposed Sale	19.80	6,287	124,452		Jan 06 05:33 PM
Myszkowski Kenneth Allen	Officer	Jan 06 '25	Proposed Sale	19.82	5,817	115,320		Jan 06 05:26 PM
Hamilton James C	Officer	Jan 06 '25	Proposed Sale	19.82	32,729	648,743		Jan 06 05:19 PM
O'Brien Patrick	Officer	Jan 06 '25	Proposed Sale	19.82	29,184	578,456		Jan 06 05:05 PM
Anzalone Christopher Richard	Officer	Jan 02 '25	Proposed Sale	19.04	11,520	219,392		Jan 02 04:16 PM
OLUKOTUN ADEOYE Y	Director	Dec 27 '24	Sale	20.00	2,850	57,000	36,740	Dec 30 05:12 PM
OLUKOTUN ADEOYE Y	Director	Dec 27 '24	Proposed Sale	19.99	2,850	56,968		Dec 27 04:23 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 23 '24	Sale	19.59	12,563	246,109	3,775,772	Dec 23 04:39 PM
Anzalone Christopher Richard	Officer	Dec 23 '24	Proposed Sale	19.59	12,563	246,085		Dec 23 04:16 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 18 '24	Sale	21.24	26,712	567,486	3,688,335	Dec 20 06:04 PM
Waddill William D.	Director	Dec 17 '24	Sale	22.04	3,747	82,584	40,378	Dec 18 06:19 PM
Waddill William D.	Director	Dec 16 '24	Sale	21.90	3,748	82,081	44,125	Dec 18 06:19 PM
GIVEN DOUGLAS B	Director	Dec 16 '24	Sale	21.90	5,000	109,500	124,714	Dec 18 06:18 PM
GIVEN DOUGLAS B	Director	Dec 17 '24	Sale	22.04	547	12,056	124,167	Dec 18 06:18 PM
Vakiener Victoria	Director	Dec 16 '24	Sale	21.91	8,994	197,059	21,211	Dec 18 06:15 PM
Anzalone Christopher Richard	Officer	Dec 18 '24	Proposed Sale	21.24	26,712	567,415		Dec 18 04:41 PM
GIVEN DOUGLAS B	Director	Dec 17 '24	Proposed Sale	21.98	547	12,026		Dec 17 05:06 PM
Waddill William D.	Director	Dec 17 '24	Proposed Sale	22.03	3,747	82,552		Dec 17 04:53 PM
Waddill William D.	Director	Dec 16 '24	Proposed Sale	21.89	3,748	82,056		Dec 16 04:44 PM
Vakiener Victoria	Director	Dec 16 '24	Proposed Sale	21.91	8,994	197,066		Dec 16 04:30 PM
GIVEN DOUGLAS B	Director	Dec 16 '24	Proposed Sale	21.89	5,000	109,470		Dec 16 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARWR

Arrowhead Pharmaceuticals Inc

Upgrade your FINVIZ experience